John Thomas Howard, treasurer and director of Canadian healthcare company CANARX, was arrested Sunday on charges of smuggling and conspiracy, with federal authorities accusing him of running a years-long scheme to illegally import prescription drugs into the United States. His brother, company president Bob Howard, remains wanted. Court records filed Tuesday also charge John Thomas Howard with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.
The criminal complaint covers alleged violations from February 2017 to April 2026.
CANARX, based in Windsor, Ontario, describes itself as the first international prescription provider for the U.S., sourcing medications from Canada, the United Kingdom, Australia and New Zealand. It operates as what is known as an alternative funding program (AFP), a model that has become more widespread as U.S. drug costs rise. AFPs offer high-cost specialty drugs through employers at reduced prices, often by shipping the medications directly from overseas, a practice federal authorities say is illegal and poses safety risks.
The company has faced years of scrutiny from the Food and Drug Administration. In 2019, the FDA sent a warning letter stating that CANARX was operating 'in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs.' In 2023, the agency seized medication being shipped by the company that it said was potentially misbranded and counterfeit.
Joseph Morris, the company's general counsel, told CNBC in a statement: 'The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court.'
The affidavit from FDA special agent Dustin Dobbs says the FDA's investigation found probable cause to believe CANARX illegally imported or caused the illegal importation of prescription drugs, though it does not specify which medications.
The case highlights the legal question at the heart of the AFP business model. The FDA allows import of prescription drugs for personal use in limited circumstances, but a spokesperson said last year that 'in most circumstances, a person cannot import prescription drugs from other countries into the U.S. ... as substitutes for FDA-approved drugs.'
Separately, in a pending civil lawsuit, Gilead Sciences has accused CANARX and other companies of illegally importing Biktarvy, its HIV medication. A Gilead spokesperson said the company 'has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain. We welcome the government's efforts to hold accountable those whose conduct may put patients at risk.' CANARX has not responded to that lawsuit.
Analysis
Why This Matters
- The case puts alternative funding programs, which serve thousands of U.S. patients, under legal threat.
- It tests the limits of the FDA's personal-importation policy.
- Employers that require staff to use AFPs could face liability questions.
Background
Alternative funding programs emerged as a way to reduce drug costs by sourcing medications overseas. The FDA has long held that importing foreign drugs as substitutes for domestic ones is generally illegal. CANARX has been under FDA scrutiny since 2019, when it received a warning letter, and in 2023 the agency seized some of the company's shipments. The current charges represent a significant escalation in enforcement.
Key Perspectives
- U.S. authorities (FDA, DOJ): allege that CANARX illegally imported prescription drugs over nearly a decade, violating federal smuggling and drug laws.
- CANARX: through its general counsel, denies the charges and says it will defend vigorously. The company had previously argued its operations were legal and that drugs came from highly regulated countries.
- Gilead Sciences: has filed its own civil suit against CANARX over HIV drug imports and supports the government's enforcement action.
- FDA: holds that importing foreign drugs as substitutes for FDA-approved drugs is not permitted in most cases, contrary to the model used by AFPs.
What to Watch
- Whether Bob Howard is taken into custody.
- The progress of the criminal case, including any plea entry.
- Developments in Gilead's pending civil lawsuit against CANARX.
Checked
12 claims in this story checked against 1 source: 10 supported.
Show each claim
- SupportedU.S. authorities arrested a CANARX official.Business News: “John Thomas Howard, treasurer and a director of the company, CANARX, was arrested Sunday on smuggling and conspiracy charges, according to the records.”
- SupportedAuthorities allege a scheme to illegally import prescription drugs into the U.S.Business News: “U.S. authorities are accusing the two top officials of a Canadian company of operating a long-running scheme to illegally import prescription drugs into the U.S., according to court records filed Tuesday.”
- SupportedTreasurer John Thomas Howard faces smuggling and conspiracy charges.Business News: “John Thomas Howard, treasurer and a director of the company, CANARX, was arrested Sunday on smuggling and conspiracy charges, according to the records.”
- SupportedBob Howard, John Thomas Howard’s brother and CANARX’s president, is wanted.Business News: “Bob Howard, his brother, who is president and a director of CANARX, is also wanted in the federal investigation, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations.”
- Partly supportedCourt records filed Tuesday also charge John Thomas Howard with introducing misbranded drugs into interstate commerce and illegal drug importation.Business News: “Besides conspiracy and smuggling, the arrest warrant said John Thomas Howard was charged with introducing misbranded drugs into interstate commerce and illegal drug importation.”
- SupportedThe 2019 FDA warning letter said CANARX was operating “in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs.”Business News: “In 2019, the FDA sent a warning letter to the company, saying it was operating "in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs."”
- SupportedJoseph Morris, the company’s general counsel, told CNBC: “The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court.”Business News: “The company's general counsel, Joseph Morris, told CNBC in a statement: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court."”
- SupportedFDA special agent Dustin Dobbs’s affidavit says the FDA investigation found probable cause to believe CANARX illegally imported or caused the illegal importation of prescription drugs, and does not specify which medications.Business News: “The affidavit said that the FDA's investigation found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States …." The affidavit does not specify which medications”
- Partly supportedThe FDA allows prescription-drug imports for personal use in limited circumstances.Business News: “The FDA allows Americans to import medications for individual use in some cases if the drug is not available domestically.”
- SupportedAn FDA spokesperson said last year that “in most circumstances, a person cannot import prescription drugs from other countries into the U.S. ... as substitutes for FDA-approved drugs.”Business News: “But an FDA spokesperson told CNBC last year that "in most circumstances, a person cannot import prescription drugs from other countries into the U.S. ... as substitutes for FDA-approved drugs."”
- SupportedIn a pending civil lawsuit, Gilead Sciences accused CANARX and other companies of illegally importing Biktarvy, its HIV medication.Business News: “In a separate civil lawsuit that is pending, Gilead Sciences accused CANARX and other companies of illegally importing Biktarvy, its medication to treat HIV.”
- SupportedA Gilead spokesperson said the company “has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain. We welcome the government's efforts to hold accountable those whose conduct may put patients at risk.”Business News: “In a statement to CNBC on Wednesday, a Gilead spokesperson said the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain. We welcome the government's efforts to hold accountable those whose conduct may put patients at risk."”